These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20080332)

  • 1. New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma.
    Babjuk M
    Eur Urol; 2010 May; 57(5):774-6; author reply 776-7. PubMed ID: 20080332
    [No Abstract]   [Full Text] [Related]  

  • 2. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
    Rouprêt M; Guillotreau J; Irani J; Zerbib M
    Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
    Soloway MS; Arianayagam M
    Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
    [No Abstract]   [Full Text] [Related]  

  • 9. Urothelial cancers: using biology to improve outcomes.
    Pezaro C; Liew MS; Davis ID
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
    Pollera CF; Nelli F
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience.
    Kurth KH; Sylvester R; de Pauw M; ten Kate F
    Prog Clin Biol Res; 1989; 310():125-45. PubMed ID: 2672012
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of transitional cell carcinoma of the bladder in a juvenile patient].
    Koroku M; Tanda H; Kato S; Onishi S; Nakajima H; Nanbu A; Nitta T; Akagashi K
    Hinyokika Kiyo; 1999 Oct; 45(10):711-2. PubMed ID: 10586365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When does superficial bladder cancer resist intravesical therapy?
    Vögeli T; Ackermann R
    Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
    [No Abstract]   [Full Text] [Related]  

  • 15. Incrusted cystitis after intravesical mitomycin C treatment.
    Llopis M; Moreno J; Botella R; Algado M
    Acta Urol Belg; 1993 Sep; 61(3):21-3. PubMed ID: 8256682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
    Boyd LA
    Urol Nurs; 2003 Jun; 23(3):189-91, 199; quiz 192. PubMed ID: 12861735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions).
    Bouffioux C; van der Meijden A; Kurth KH; Jakse G; Bono A; Hall R; Oosterlinck W; Sylvester R
    Prog Clin Biol Res; 1992; 378():29-42. PubMed ID: 1301584
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
    Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
    J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    de Reijke TM
    Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.